Breast Surgery

Dental Surgery

General Surgery

Gynecological Surgery

Head and Neck Surgery

Neurological Surgery


ROS1 fusions are absent in a series of 109 pancreatic ductal adenocarcinomas


J. Lke1, Z. Madarasz2, A. Schad3, S. Schrewe1, W. Roth3, W. Hiller2, T. Hansen1

Institut fr Pathologie, Klinikum Lippe

Correspondence to Author: J.Lke


1.1. Objective: Pancreatic ductal adenocarcinoma (PDAC) accounts for up to 95% of all malignant pancreatic neoplasms and constitutes the most frequent histopathologic entity among pancreatic neoplasms. Prognosis is mainly dependent on the stage of disease at diagnosis and overall outcomes are poor. KRAS-mutants are frequently observed in PDAC. There is, however, a percentage of PDAC cases with wild-type KRAS. ROS1 is a tyrosine kinase that has been recognized as a promising therapeutic target, when rearranged. Rearrangements have rarely been reported to be present in malignancies of the pancreato-biliary system, such as cholangiocarcinoma.


ROS1 fusions, pancreatic ductal, adenocarcinomas


J.Luke. ROS1 fusions are absent in a series of 109 pancreatic ductal adenocarcinomas. World Journal of Clinical Surgery 2020.

Journal Info

  • Journal Name: World Journal of Clinical Surgery
  • Impact Factor: 2.709**
  • ISSN: 2766-6182
  • DOI: 10.52338/wjsurgy
  • Short Name: WJCSR
  • Acceptance rate: 55%
  • Volume: 6 (2024)
  • Submission to acceptance: 25 days
  • Acceptance to publication: 10 days


  • Crossref indexed journal
  • Publons indexed journal
  • Pubmed-indexed journal
  • International Scientific Indexing (ISI)-indexed journal
  • Eurasian Scientific Journal Index (ESJI) index journal
  • Semantic Scholar indexed journal
  • Cosmos indexed journal


  • International Reach
  • Peer Review
  • Rapid Publication
  • Open Access
  • High Visibility